Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Subha Vogeti"'
Autor:
Daniel L. Flynn, Michael Clare, Lance J. Stewart, Lawrence Chun, Karen M. Yates, Subha Vogeti, Lakshminarayana Vogeti, Hanumaiah Telikepalli, Thiwanka Samarakoon, Thomas J. Rutkoski, William C. Patt, Tristan W. Patt, Wei-Ping Lu, Molly M. Hood, Carol L. Ensinger, Timothy M. Caldwell, R. John Booth, Yu Mi Ahn, Scott C. Wise, Benjamin A. Turner, Cynthia B. Leary, Michael D. Kaufman, Bryan D. Smith
Altiratinib (DCC-2701) was designed based on the rationale of engineering a single therapeutic agent able to address multiple hallmarks of cancer (1). Specifically, altiratinib inhibits not only mechanisms of tumor initiation and progression, but als
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a49f1af80ca00d7cc02eb5848964921
https://doi.org/10.1158/1535-7163.c.6536815.v1
https://doi.org/10.1158/1535-7163.c.6536815.v1
Autor:
Daniel L. Flynn, Michael Clare, Lance J. Stewart, Lawrence Chun, Karen M. Yates, Subha Vogeti, Lakshminarayana Vogeti, Hanumaiah Telikepalli, Thiwanka Samarakoon, Thomas J. Rutkoski, William C. Patt, Tristan W. Patt, Wei-Ping Lu, Molly M. Hood, Carol L. Ensinger, Timothy M. Caldwell, R. John Booth, Yu Mi Ahn, Scott C. Wise, Benjamin A. Turner, Cynthia B. Leary, Michael D. Kaufman, Bryan D. Smith
Supplementary Materials and Methods. Supplementary table 1: XRay crystallography parameters for DP-4157/MET complex. Supplementary table 2: Source and description of kinases. Supplementary table 3: Selectivity of profile of altiratinib inhibition fro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b914b7bf5b2f07136ac99e3d894850d
https://doi.org/10.1158/1535-7163.22501534
https://doi.org/10.1158/1535-7163.22501534
Autor:
Timothy M. Caldwell, Michael D. Kaufman, Scott C. Wise, Yu Mi Ahn, Molly M. Hood, Wei-Ping Lu, William C. Patt, Thiwanka Samarakoon, Lakshminarayana Vogeti, Subha Vogeti, Karen M. Yates, Stacie L. Bulfer, Bertrand Le Bourdonnec, Bryan Smith, Daniel Flynn
Publikováno v:
Bioorganicmedicinal chemistry letters. 74
Based on the structure of an early lead identified in Deciphera's proprietary compound collection of switch control kinase inhibitors and using a combination of medicinal chemistry guided structure activity relationships and structure-based drug desi
Autor:
Stacie L. Bulfer, Bertrand Le Bourdonnec, Jeffery D. Zwicker, Yu Mi Ahn, Gada Al-Ani, Hikmat Al-Hashimi, Chase Crawley, Kristin M. Elliott, Saqib Faisal, Andrew M. Harned, Cale L. Heiniger, Molly M. Hood, Salim Javed, Michael Kennedy, Joshua W. Large, Cynthia B. Leary, Wei-Ping Lu, Kylie Luther, Max D. Petty, Hunter R. Picard, Justin T. Proto, Yeni K. Romero, Forrest A. Stanley, Kristen L. Stoltz, Daniel C. Tanner, Hanumaiah Telikepalli, Mary J. Timson, Lakshminarayana Vogeti, Subha Vogeti, Sihyung Yang, Lexy H. Zhong, Bryan D. Smith, Daniel L. Flynn
Publikováno v:
Cancer Research. 83:4045-4045
Background: Mutations in the RAS/MAPK pathway are a frequent driver of cancer, with oncogenic RAS or RAF mutations occurring in >30% of all cancers. First generation BRAF inhibitors are approved for use for tumors with Class I BRAF mutations (V600X).
Autor:
Bryan D. Smith, Subha Vogeti, Timothy M. Caldwell, Hanumaiah Telikepalli, Yu Mi Ahn, Gada Al-Ani, Stacie L. Bulfer, Andrew Greenwood, Cale L. Heiniger, Joshua W. Large, Cynthia B. Leary, Wei-Ping Lu, Kylie Luther, William C. Patt, Max D. Petty, Yeni K. Romero, Forrest A. Stanley, Kristen L. Stoltz, Daniel C. Tanner, Sihyung Yang, Yu Zhan, Bertrand Le Bourdonnec, Daniel L. Flynn
Publikováno v:
Cancer Research. 83:4033-4033
Introduction: Gastrointestinal stromal tumors (GISTs) are typically driven by primary mutations in KIT exons 9 or 11. Heterogeneous drug-resistant secondary mutations arise in patients treated with FDA approved KIT inhibitors, including imatinib and
Autor:
Timothy M. Caldwell, Yu Mi Ahn, Stacie L. Bulfer, Cynthia B. Leary, Molly M. Hood, Wei-Ping Lu, Lakshminarayana Vogeti, Subha Vogeti, Michael D. Kaufman, Scott C. Wise, Bertrand Le Bourdonnec, Bryan Smith, Daniel Flynn
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 74:128928
Based on knowledge of kinase switch-control inhibition and using a combination of structure-based drug design and standard medicinal chemistry principles, we identified a novel series of dihydropyrimidone-based CSF1R kinase inhibitors displaying exqu
Autor:
Scott C. Wise, Gege Tan, Wei-Ping Lu, Michael Kaufman, Breelyn A. Wilky, Subha Vogeti, Yu Mi Ahn, Daniel L. Flynn, Rodrigo Ruiz-Soto, Bryan D. Smith, Maitreyi Sharma, Timothy M. Caldwell, Lakshminarayana Vogeti, Cynthia B. Leary, Lara E. Davis
Publikováno v:
Molecular cancer therapeutics. 20(11)
Macrophages can be co-opted to contribute to neoplastic, neurologic, and inflammatory diseases. Colony-stimulating factor 1 receptor (CSF1R)-dependent macrophages and other inflammatory cells can suppress the adaptive immune system in cancer and cont
Autor:
Molly M. Hood, Arin McKinley, Bryan D. Smith, Subha Vogeti, Gada Al-Ani, Wei Ping Lu, Ying Su, Ajia Town, Timothy M. Caldwell, Daniel L. Flynn, Lakshminarayana Vogeti, Michael Heinrich, Cynthia B. Leary, Patt William Chester, Lawrence Chun, Benjamin A. Turner, Oliver Rosen, Albiruni Ryan Abdul Razak, Karen M. Yates, Michael Kaufman, Carol L. Ensinger, Filip Janku, Rodrigo Ruiz-Soto, Hanumaiah Telikepalli, Yu Mi Ahn, Anu Gupta, Thomas J. Rutkoski, Stacie L. Bulfer, Scott C. Wise
Publikováno v:
Cancer cell. 35(5)
Ripretinib (DCC-2618) was designed to inhibit the full spectrum of mutant KIT and PDGFRA kinases found in cancers and myeloproliferative neoplasms, particularly in gastrointestinal stromal tumors (GISTs), in which the heterogeneity of drug-resistant
Autor:
Senait Alemayehu, Jonathan S. Rosenblum, Geeta Sharma, Tyzoon K. Nomanbhoy, Arwin Aban, Maria Sykes, John W. Kozarich, Subha Vogeti, Jiangyue Wu, Heidi E. Brown
Publikováno v:
Biochemistry. 55:5434-5441
Palbociclib is a cyclin-dependent kinase (CDK) 4/CDK6 inhibitor approved for breast cancer that is estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative. We profiled palbociclib in cells either sensitive or resi
Autor:
Bryan D. Smith, Lakshminarayana Vogeti, Quanrong Shen, Cynthia B. Leary, Chase K Crawley, Karen M. Yates, Cale L Heiniger, Hikmat Al-Hashimi, Timothy M. Caldwell, Anu Gupta, Mary J Timson, Hanumaiah Telikepalli, Justin T Proto, Daniel L. Flynn, Gada Al-Ani, Subha Vogeti, Wei-Ping Lu, Jarnail Singh, Yu Mi Ahn, Stacie L. Bulfer
Publikováno v:
Molecular Cancer Therapeutics. 18:B129-B129
Background: Cancer cells activate autophagy, a catabolic process to resupply nutrients and recycle damaged organelles, in order to survive stresses such as limited nutrients and hypoxia, or chemotherapy treatments. RAS mutant cancers, in particular,